| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7460 R25138 |
Putignano (Valproate), 2019 | Apgar score at 5 min < 7 | during pregnancy (anytime or not specified) | retrospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.17 [0.14;9.78] C | 1/131 6/917 | 7 | 131 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5931 R15127 |
Artama (Valproate) (Controls exposed to Lamotrigine, sick), 2013 | 5-min Apgar <7 | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.32 [0.34;5.19] C excluded (control group) |
7/235 3/132 | 10 | 235 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5911 R14906 |
Artama (Valproate) (Controls unexposed, disease free), 2013 | 5-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
2.72 [1.28;5.81] excluded (control group) |
7/235 3,014/269,151 | 3,021 | 235 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5919 R15002 |
Artama (Valproate) (Controls unexposed, sick), 2013 | 5-min Apgar <7 | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 2.68 [0.91;7.94] | 7/235 3/652 | 10 | 235 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6353 R17320 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) b, 2013 | Low Apgar score (< 7 at 5 min) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.66 [0.36;19.54] C excluded (control group) |
2/40 2/103 | 4 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5506 R17324 |
Veiby (Valproate) (Controls unexposed, disease free) b, 2013 | Low Apgar score (< 7 at 5 min) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
1.60 [0.20;11.80] excluded (control group) |
2/40 1,710/106,899 | 1,712 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6350 R17328 |
Veiby (Valproate) (Controls unexposed, sick) b, 2013 | Low Apgar score (< 7 at 5 min) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.20 [0.46;10.58] C | 2/40 9/386 | 11 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6416 R17617 |
Pennell (Valproate), 2012 | Apgar score (at 5 minutes < 7) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 8.11 [0.38;171.84] C | 2/62 0/97 | 2 | 62 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6261 R16734 |
Borthen (Valproate) (Controls exposed to Lamotrigine, sick), 2010 | Apgar < 7 after 5 minutes | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.46 [0.12;1.79] C excluded (control group) |
3/215 7/233 | 10 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5684 R16679 |
Borthen (Valproate) (Controls unexposed, disease free), 2010 | Apgar < 7 after 5 minutes | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.00 [0.30;3.20] excluded (control group) |
3/215 6,022/362,302 | 6,025 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6263 R16750 |
Borthen (Valproate) (Controls unexposed, sick), 2010 | Apgar < 7 after 5 minutes | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.86 [0.26;2.86] C | 3/215 30/1,863 | 33 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5495 R16633 |
Jäger-Roman (Valproate), 1986 | Low Apgar score (0 to 6 after 5 minute) | at least 1st trimester excluded | prospective cohort | unexposed (general population or NOS) | Adjustment: No |
11.09 [0.49;249.88] C excluded (exposition period) |
2/14 0/26 | 2 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.78 [0.92;3.45] | 63 | 683 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Valproate; 2: Valproate) (Controls unexposed, sick; 3: Valproate) (Controls unexposed, sick) ; 4: Valproate; 5: Valproate) (Controls unexposed, sick;
Asymetry test p-value = 0.6039 (by Egger's regression)
slope=0.0324 (0.9967); intercept=0.7635 (1.3214); t=0.5778; p=0.6039
excluded 6261, 5684, 5931, 5911, 6353, 5506